• Download mobile app
16 Jul 2024, Edition - 3290, Tuesday

Trending Now

  • My aim is to make India the third most economically powerful country. I’ve vowed to work three times more in my third term: PM Modi to the Indians in Russia
  • Rahul Gandhi who goes to Hatras does not bother about the deaths in Kallakuruchi: Union Minister L Murugan.
  • All those who killed Armstrong will be arrested and brought to justice: MK Stalin promises Armstrong ‘s parents and his wife
  • Law and Order will not get any better by changing the police officers. Law and Order has totally collapsed in DMK’s regime.: EPS


India’s Leading Business Families Invest in NeuroLeap

by businesswireindia.com

Business Wire India
Rajashree Birla, Chairperson, Aditya Birla centre for community initiatives & rural development and Sminu Jindal, MD, Jindal Saw & founder chairperson, Svayam, have picked up stakes in NeuroLeap, a brain enhancement & mental health venture, founded by Kumaar Bagrodia, for an undisclosed amount. Bagrodia is an Oxford educated entrepreneur & BCI pro based in Mumbai.
NeuroLeap uses advanced BCI Brain Computer Interface technology to safely understand brain activity and help it perform at optimum potential; completely non-invasively, without using any medication and with zero side effects. At its centres in Mumbai & New Delhi, NeuroLeap has successfully delivered brain enhancement for various areas like attention, executive function, calmness, sleep, memory and emotional health for people from all walks of life, across age groups who may or may not have any mental disorders. It has been successfully treating people with severe mental health conditions such as anxiety, clinical depression, insomnia, attention deficit hyperactivity disorder – ADHD, dyslexia, autism, addiction, eating disorders, migraine and tinnitus, among others. The science is evidence based & the technology backed by NASA, DARPA, the US Army, Navy, Airforce, US National Institute of Health and relevant parts are US FDA registered. NeuroLeap has now successfully developed India specific know-how across different mental health disorders.
IIT has also signed an MoU with NeuroLeap for promoting research in BCI technology for neuro enhancement. “NeuroLeap is the leading company in India offering advanced neurotechnology based brain assessment and improvement,” said Prof Vinod Prasad, Dean industry collaboration, IIT Palakkad.
“…Congratulations to Kumaar Bagrodia for fronting NeuroLeap; it is indeed cutting edge…I believe NeuroLeap will help fill in the void, provide relief pan India. I wish Kumaar every success every step of the way,” said Padma Bhushan awardee Rajashree Birla.
Jindal says, “NeuroLeap is successfully delivering better brain outcomes. Bagrodia is a visionary entrepreneur and is steadily building the future of mental health and wellness in India. I'm happy to invest in the venture which is leveraging innovative technology for a more advanced way to understand the brain and safely enhance it without pharma or medical interventions.”
India faces severe challenges in the area of mental health. A WHO study expects 20% of the Indian population to be affected by next year and an ASSOCHAM survey shows that 42.5% of corporate employees in India suffer from depression or general anxiety. The honourable President of India Shri Ram Nath Kovind has earlier said that India faces a possible mental health epidemic and called for a national mission to deal with it.
“This is the new age of brain enhancement & mental health, which is safe & technology based. Our clients who have benefited include businessmen, professionals, homemakers, students, celebrities, leaders who are achievers in their fields and naturally want to stay fit not just physically but mentally as well; even enhance various areas of their brain function & emotions. We have helped clients with various mental health disorders lead healthier, happier, fulfilling & enriched lives,” said Bagrodia, adding investments by Birla and Jindal will encourage the company to grow its presence across the country.

Website: www.NeuroLeap.Science
Source: Businesswire